Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Friday, September 12, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has received shareholder approval for the acquisition of SKNY Pharmaceuticals. This strategic move enhances MIRA's pipeline with SKNY-1, an oral therapeutic candidate that has shown promising results in preclinical studies, including up to 30% weight loss and reversal of nicotine cravings. The acquisition positions MIRA to advance its focus on metabolic disorders.
Price reaction · baseline $1.66 (2025-09-11 close) · hit pre-market · 1 other MIRA headline(s) in the window, move may be shared
day 0 close
-12.7%
day 1
-16.9%
day 3 · peak
-22.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition strengthens MIRA's pipeline.
  • SKNY-1 shows potential for significant weight loss.
  • Candidate may aid in nicotine craving reversal.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL / ACCESS Newswire / September 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its stockholders have a…
You can read the full content here

Frequently Asked Questions

What acquisition did MIRA Pharmaceuticals announce?

MIRA Pharmaceuticals announced the acquisition of SKNY Pharmaceuticals.

What is SKNY-1?

SKNY-1 is an oral therapeutic candidate for obesity and smoking cessation.

What results did SKNY-1 show in studies?

SKNY-1 demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies.

What is MIRA Pharmaceuticals focused on?

MIRA Pharmaceuticals focuses on developing therapeutics for neurologic, neuropsychiatric, and metabolic disorders.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals SKNY Pharmaceuticals obesity treatment nicotine cessation SKNY-1
Last updated: Sep 12, 2025

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →